Leader

Hormone replacement therapy and the endometrium

K M Feeley¹ and M Wells²

¹ Department of Histopathology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
² Section of Oncology and Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Sheffield S10 2RX, UK

Correspondence to:
Professor Wells m.wells{at}sheffield.ac.uk

Modern hormone replacement therapy (HRT) regimens contain oestrogen and progestogen, given either in a cyclical or continuous combined manner. Most endometrial biopsies from women on sequential HRT show weak secretory features. Approximately 15% show proliferative activity, although this figure may be less if more than nine days of progestogen is given in each cycle. A small proportion will show an inactive or atrophic endometrium. Up to 50% of biopsies from women on continuous combined HRT contain minimal endometrial tissue for histopathological analysis: this correlates well with an atrophic endometrium with no appreciable pathology. Of the 50% with more substantial material, approximately one half will show endometrial atrophy, and one half will show weak secretory features. Proliferative, menstrual, and pseudodecidual changes are rare. Approximately 20% of women given unopposed oestrogen for one year develop endometrial hyperplasia. The relative risk of endometrial carcinoma is two to three. This is dramatically reduced by the addition of progestogen to the regimen, but cyclical progestogen as part of a sequential HRT regimen does not completely eliminate the risk of carcinoma. The prevalence of endometrial hyperplasia associated with sequential HRT is 5.4%, and that of atypical hyperplasia (endometrial intraepithelial neoplasia) is 0.7%. Continuous combined HRT is not associated with the development of hyperplasia or carcinoma, and may normalise the endometrium of women who have developed complex hyperplasia on sequential HRT. The probability of a histopathologist finding clinically relevant pathology in an endometrial biopsy specimen of a patient on HRT is low and is more likely to be a manifestation of pre-existing disease.

Key Words: endometrium • hormone replacement therapy • endometrial hyperplasia • endometrial carcinoma

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Clarke, B, McCluggage, W G (2009). Iatrogenic lesions and artefacts in gynaecological pathology. J. Clin. Pathol. 62: 104-112 [Abstract] [Full Text]  
• Zang, H., Sahlin, L., Masironi, B., Eriksson, E., Linden Hirschberg, A. (2007). Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women. J. Clin. Endocrinol. Metab. 92: 2169-2175 [Abstract] [Full Text]  
• McCluggage, W G (2006). My approach to the interpretation of endometrial biopsies and curettings.. J. Clin. Pathol. 59: 801-812 [Abstract] [Full Text]  
• Christoffel, J, Rimoldi, G, Wuttke, W (2006). Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment.. J Endocrinol 188: 397-405 [Abstract] [Full Text]  
• Chan, R. W.S., Schwab, K. E., Gargett, C. E. (2004). Clonogenicity of Human Endometrial Epithelial and Stromal Cells. Biol. Reprod. 70: 1738-1750 [Abstract] [Full Text]  
• Blok, L. J., De Ruiter, P. E., Kuhne, E. C. M., Hanekamp, E. E., Grootegoed, J. A., Smid-Koopman, E., Gielen, S. C. J. P., De Gooyer, M. E., Kloosterboer, H. J., Burger, C. W. (2003). Progestagenic Effects of Tibolone on Human Endometrial Cancer Cells. J. Clin. Endocrinol. Metab. 88: 2327-2334 [Abstract] [Full Text]